Large state-wide variation (8.5-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2019 ^a indicates ≥1.50 SD (16.8) from the mean (31.0... by Luke R. Cavanah (19022435)

Bioinformatics analysis of the gene pathways that were enriched in the N.g MDP–treated osteocytes and verification <i>in vitro</i>. by Zheng-Rong Gao (12488388)

2‑Ethylhexyl Diphenyl Phosphate and Its Hydroxylated Metabolites are Anti-androgenic and Cause Adverse Reproductive Outcomes in Male Japanese Medaka (Oryzias latipes) by Yu Li (183836)

“…In this study, we for the first time observed that EHDPP elicited androgen receptor (AR) antagonistic activity with a 50% inhibitory concentration of 37.5 μM. 2-Ethyl-5-hydroxyhexyl diphenyl phosphate was proved to be the dominant metabolite of EHDPP in Japanese medaka and elicited 3.1-fold stronger AR antagonistic activity than that of EHDPP. …”

2‑Ethylhexyl Diphenyl Phosphate and Its Hydroxylated Metabolites are Anti-androgenic and Cause Adverse Reproductive Outcomes in Male Japanese Medaka (Oryzias latipes) by Yu Li (183836)

“…In this study, we for the first time observed that EHDPP elicited androgen receptor (AR) antagonistic activity with a 50% inhibitory concentration of 37.5 μM. 2-Ethyl-5-hydroxyhexyl diphenyl phosphate was proved to be the dominant metabolite of EHDPP in Japanese medaka and elicited 3.1-fold stronger AR antagonistic activity than that of EHDPP. …”

Relative expression (fold-change) of immune genes in mitogen-stimulated splenic lymphocytes. by Chaiwat Monmai (6377270)

Average packets rate. by Longyan Ran (18452261)

List of 186 genes that were increased more than 2-fold from control to galactose and decreased more than 1.5-fold from galactose to 2ME2. by Masaru Takashima (13851129)

VPS34 inhibition decreases intracellular levels of cholesteryl-esters, blocks cholesterol uptake and enhances lysosomal degradation of LDLR. by Marek J. Kobylarz (9292599)

S5 Fig - by Meihui Chen (1670020)

Schematic representation of eNOS-siRNA delivery by UMMD treatment to inhibit angiogenesis in blood vessels. by Elisa Villa-Martínez (19287685)

Model performance according to number of variables by 5-fold cross-validation. by Gazi Md. Salahuddin Mamun (13905678)

Primary endpoint analysis, i.e., time to first occurrence of combined event of 50% decrease in eGFR or ESRD. by Rozita Mohd (7411322)

Genes showing 1.5 fold expression decrease in D381 relative to heterozygous <i>TOR1/tor1</i>. by Wanjun Qi (5571359)

GREAT GO analysis of WDR5 and MYCN overlapped ChIP-seq peaks with >2.5-fold decrease of WDR5 signal intensity after the silencing of <i>WDR5</i>. by Zhihui Liu (95891)

“…<p>GREAT GO analysis of WDR5 and MYCN overlapped ChIP-seq peaks with >2.5-fold decrease of WDR5 signal intensity after the silencing of <i>WDR5</i>.…”

Affinity analysis results (with a confidence level above 50%). by Marta R. Jabłońska (8491404)

5-fold validation results for model training with sex-specific data. by M. Mendez (6624953)

Decreased expression of Rho in the <i>nrl</i>-KO retinas as detected by dot blotting. by Fei Liu (21082)

Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

Drugs susceptibility profile (EC₅₀ values and Fold-change) to the antileishmanials in all polyene resistant lines of <i>Leishmania</i> spp. by Edubiel A. Alpizar-Sosa (13848145)

“…Values higher and lower than 1, indicate a decrease and increase in susceptibility, respectively.…”

Analysis of sphingosine levels from BAL. by Henning Carstens (13132801)